Double Bond Pharmaceutical, DBP, is a pharmaceutical company. The main focus is on the treatment of severe forms of cancer, infections and autoimmune diseases. The research is based on the company's proprietary technology. The products are sold under separate trademarks and collaboration on product development is done together with other players in the field. The company is based in Uppsala.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Igor Lokot | 17,46 | 29,02 | 2021-09-30 |
| Avanza Pension | 5,76 | 4,95 | 2021-09-30 |
| Per Ahlström | 2,52 | 2,17 | 2021-09-30 |
| Magnus Hamberg | 2,17 | 1,87 | 2021-09-30 |
| Obain AB | 2,08 | 1,79 | 2021-09-30 |
| KSDR Hamberg AB | 1,81 | 1,56 | 2021-09-30 |
| Dan Peters | 1,81 | 1,56 | 2021-09-30 |
| Gunilla Paalberg | 1,68 | 1,44 | 2021-09-30 |
| Jan Johan Paalberg | 1,65 | 1,42 | 2021-09-30 |
| Rejo AB | 1,27 | 1,09 | 2021-09-30 |
2022-02-25 Bokslutskommuniké 2021
2022-05-04 Delårsrapport 2022-Q1